Literature DB >> 15464239

Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.

Sean W P Koppe1, Atul Sahai, Padmini Malladi, Peter F Whitington, Richard M Green.   

Abstract

BACKGROUND/AIMS: Feeding mice a methionine choline deficient (MCD) diet serves as a nutritional model of non-alcoholic steatohepatitis (NASH). NASH and alcohol-induced steatohepatitis are histologically similar, suggesting a similar pathogenesis. Pentoxifylline (PTX) attenuates TNF-alpha production, acts as an antioxidant and decreases mortality in alcoholic steatohepatitis. The aim of our study is to determine if PTX attenuates MCD diet induced steatohepatitis and determine the mechanism of this effect.
METHODS: Mice were placed on an MCD or control diet for 2 weeks and were treated with or without PTX. Serum ALT, liver histology, and inflammatory mechanisms were evaluated.
RESULTS: PTX attenuates MCD diet induced steatohepatitis, decreasing both serum ALT levels and hepatic inflammation. Serum ALT levels were reduced approximately 50% in the MCD+PTX group compared to the MCD group. Hepatic glutathione levels were significantly higher in the MCD+PTX group compared to the MCD group. There was also a reduction in TNF-alpha mRNA in female mice treated with PTX. MCD+PTX mice had increased hepatic triglyceride content compared to the MCD mice, but less histologic evidence of inflammation despite the increased steatosis. Serum lipid and bile salt levels also were similar in PTX and vehicle control treated mice.
CONCLUSIONS: PTX decreases serum ALT levels and hepatic inflammation in the MCD model of steatohepatitis, likely via increasing glutathione levels or reducing TNF-alpha expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464239     DOI: 10.1016/j.jhep.2004.06.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  50 in total

1.  Decreased accumulation of ultrasound contrast in the liver of nonalcoholic steatohepatitis rat model.

Authors:  Yuki Miyata; Takeo Miyahara; Fuminori Moriyasu
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Treatment options for nonalcoholic Fatty liver disease.

Authors:  Shivakumar Chitturi
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

3.  Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice.

Authors:  Wing-Kin Syn; Liu Yang; Dian Jung Chiang; Yue Qian; Youngmi Jung; Gamze Karaca; Steve S Choi; Rafal P Witek; Alessia Omenetti; Thiago A Pereira; Anna Mae Diehl
Journal:  Liver Int       Date:  2009-04-20       Impact factor: 5.828

Review 4.  Pharmacological agents for NASH.

Authors:  Vlad Ratziu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-15       Impact factor: 46.802

5.  Effect of Pentoxifylline on Histological Activity and Fibrosis of Nonalcoholic Steatohepatitis Patients: A One Year Randomized Control Trial.

Authors:  Shahinul Alam; Skm Nazmul Hasan; Golam Mustafa; Mahabubul Alam; Mohammad Kamal; Nooruddin Ahmad
Journal:  J Transl Int Med       Date:  2017-09-30

6.  N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis.

Authors:  January N Baumgardner; Kartik Shankar; Leah Hennings; Emanuele Albano; Thomas M Badger; Martin J J Ronis
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

Review 7.  Pathophysiological basis for antioxidant therapy in chronic liver disease.

Authors:  Jesús Medina; Ricardo Moreno-Otero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.

Authors:  James P Luyendyk; Bradley P Sullivan; Grace L Guo; Ruipeng Wang
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

Review 9.  Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.

Authors:  Jacquelyn J Maher; Pablo Leon; James C Ryan
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

10.  Contribution of gut bacteria to liver pathobiology.

Authors:  Gakuhei Son; Michael Kremer; Ian N Hines
Journal:  Gastroenterol Res Pract       Date:  2010-07-28       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.